Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ImmUniverse

Financiado

Cerrado

Better control and treatment of immune mediated diseases by exploring the univer...

Better control and treatment of immune mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsies Immune-mediated diseases (IMIDs) are an increasing medical burden in industrialized countries worldwide. IMIDs are characterized by an enormous heterogeneity with regard to disease outcome and response to targeted therapies, which... ver más

31/12/2024

HUNIMED

31M€

Presupuesto del proyecto: 31M€

Líder del proyecto

HUMANITAS UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 33 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-12-31

IMI2-2018-15-03: Microenvironment imposed signatures...

I+D

Cerrada hace 6 años

0% 50% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

33 Participantes

HUNIMED

1.99M€ | Lider

CESPA COMPAÑÍA ESPAÑOLA DE S...

727.77K€ | Participante

EUROPEAN FEDERATION OF ASTHM...

Eli Lilly

4.50M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

IBD-CHARACTER Inflammatory Bowel Disease CHARACTERization by a multi modal... 8M€ Cerrado

PID2020-119032RB-I00 MEDICINA DE PRECISION EN ENFERMEDADES AUTOINMUNES: INTEGRACI... 145K€ Cerrado

ScleroTest A rapid and cost effective point of care diagnostic kit able... 71K€ Cerrado

MITI 2 Gut Microbiota-Induced Tregs for Inflammatory-Bowel-Disease... 6M€ Cerrado

REINFORCE Inflammatory Bowel Disease an EU NZ integrated approach for... 536K€ Cerrado

PREVALUNG EU Biomarkers affecting the transition from cardiovascular dise... 7M€ Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2019-12-17
Fecha Fin: 2024-12-31

Líder del proyecto

HUMANITAS UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 31M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Immune-mediated diseases (IMIDs) are an increasing medical burden in industrialized countries worldwide. IMIDs are characterized by an enormous heterogeneity with regard to disease outcome and response to targeted therapies, which currently cannot be adequately anticipated to tailor individual patient management. Hence, mechanistic understanding of this heterogeneity and biomarkers predictive for disease control and therapy response over time are important prerequisites of a future precision medicine in IMIDs. ImmUniverse has been formed as a European transdisciplinary consortium to tackle these unmet needs and to understand the role of the crosstalk between tissue microenvironment and immune cells in disease progression and response to therapy of two different IMIDs: ulcerative colitis and atopic dermatitis. Following this unique cross-disease approach ImmUniverse will fill the gap and the limitations of current studies, which do not systematically compare the complex interactions between recirculating immune cells and the respective tissue microenvironment. The consortium will combine analysis of tissue-derived signatures with circulating signatures detectable in liquid biopsies, employing state-of-the-art profiling technologies corresponding to multi-Omics datasets. The project will also bring diagnostics in IMID to a new level by implementing disruptive non-invasive liquid-biopsy methodology in combination with novel, validated circulating biomarker assays which are expected to improve diagnosis, inform early in the clinical course on disease severity and progression and enable treatment response monitoring. The identified signature will be validated to monitor state/progression and response to therapy in prospective observational cohorts. Realization of these objectives will result in improvement of patient management, lead to increased patient well-being and will significantly reduce the socioeconomic burden of these diseases.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores